Sugi Predict

Sugi Predict / Compounds / SCHEMBL622957

SCHEMBL622957

SCHEMBL622957

CC(C)(C)OC(=O)N1CCN(c2cc(Cl)ncn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 7/20 0.56
▸ MAP4K4 O95819 1/20 0.54
▸ CKS1B P61024 2/20 0.50
▸ SKP1 P63208 2/20 0.50
▸ SKP2 Q13309 2/20 0.50
▸ POLB P06746 1/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ KIT P10721 2/20 0.47
▸ ADK P55263 1/20 0.47
▸ SMARCA2 P51531 1/20 0.45
▸ SMARCA4 P51532 1/20 0.45
▸ PBRM1 Q86U86 1/20 0.45
▸ RET P07949 1/20 0.45
▸ SUV39H2 Q9H5I1 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981254 0.96 GPR119 (0.53) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL6982726 0.90 GPR119 (0.55) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL3486712 0.89 GPR119 (0.71) GPR119MAP4K4
SCHEMBL6971773 0.89 GPR119 (0.56) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL29927438 0.86 GPR119 (0.53) GPR119MAP4K4POLBMEN1KMT2A
SCHEMBL26669649 0.85 GPR119 (0.57) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL30683399 0.84 GPR119 (0.56) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL31540073 0.84 GPR119 (0.56) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL6797934 0.84 MAP4K4 (0.60) GPR119MAP4K4CKS1BSKP1SKP2
SCHEMBL653950 0.84 GPR119 (0.56) GPR119MAP4K4CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035356-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-05 — — US disclosed
EP-4642451-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) 2025-11-05 — — EP disclosed
WO-2024145273-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) 2024-07-04 — — WO disclosed
WO-2024145273-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) 2024-07-04 — — WO disclosed
WO-2024020221-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-01-25 — — WO disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 — — US disclosed
US-9603833-B2 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-TECH UENO, LTD. (JP) 2017-03-28 — — US disclosed
EP-2886534-A1 Benzene or thiophene derivative and use thereof as VAP-1 inhibitor R-Tech Ueno, Ltd. (JP) 2015-06-24 — — EP disclosed
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR R TECH UENO LTD (JP) 2015-06-18 — — US disclosed
WO-2007056023-A2 THIAZOLE INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 — — WO disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 — — WO disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 — — WO disclosed
WO-2006094840-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-09-14 — — WO disclosed
WO-2006094840-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-09-14 — — WO disclosed
EP-0925286-B1 SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE ASTRAZENECA AB (SE) 2003-01-02 — — EP disclosed
US-6093718-A AN OXIDO-SQUALENE CYCLASE INHIBITOR, ANTICHOLESTEROL AGENT FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND LOWERING CHOLESTEROL LEVELS IN BLOOD PLASMA; TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS ZENECA LIMITED (GB) 2000-07-25 — — US disclosed
CN-1228087-A Substituted pyrimidine derivatives and their pharmaceutical use ZENECA LTD (GB) 1999-09-08 — — CN disclosed
EP-0925286-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE ZENECA LIMITED (GB) 1999-06-30 — — EP disclosed
WO-1998006705-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE ZENECA LIMITED (GB) 1998-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166525-A1 BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR VAPB, VAPA, BET1 GPR119 3327/4885MAP4K4 3898/4885CKS1B 4194/4885
US-20260035356-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE TYK2, CRBN, CSNK2A3 GPR119 4253/4885MAP4K4 890/4885CKS1B 48/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 GPR119 136/4885MAP4K4 1635/4885CKS1B 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.